RECRUITING Phase 3 ClinicalTrials.gov

Better Options for Lymphatic Filariasis Treatment

Sponsor: Medicines Development for Global Health • ClinicalTrials.gov ID: NCT07159373

Registry updated: 2026-10-07

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are: 1. Does MoxDA clear infection in people with lymphatic filariasis ? 2. Does MoxDA cause any medical problems in infected and uninfected people? Researchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems. Participants will: 1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis 2. Take 3 single doses of MoxDA or IDA, 12 months apart 3. Visit their village centre once or twice in the 1 week after each treatment for safety checkups

Interventions

MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole (Drug)
Mass drug administration with moxidectin co-administered with DEC and albendazole (MoxDA). Participants who are ineligible to receive moxidectin will be offered modified treatment options: 1. Children aged ≥ 2 years but \< 4 years - DEC, albendazole, and permethrin 5% cream 2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)
IDA - Ivermectin + DEC + albendazole (Drug)
Mass drug administration with ivermectin co-administered with DEC and albendazole (IDA). Participants who are ineligible to receive moxidectin will be offered modified treatment options: 1. Children aged \< 2 years or weight \< 15 kg - DEC, albendazole, and permethrin 5% cream 2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)

Eligibility criteria

Inclusion Criteria: 1. Provision of signed and dated informed consent. 2. Resident in one of the study locations. Exclusion Criteria: There are no exclusion criteria to participation in the study. Treatment Exclusion Criteria: Participants are ineligible to receive the treatment regimen allocated to their village if they meet any of the following criteria: 1. Severe illness (any illness that is severe enough to interfere with activities of daily living); 2. Known or suspected allergy to ivermectin, moxidectin, diethylcarbamazine or albendazole; 3. Pregnant; 4. Breastfeeding a baby within 7 days of birth; 5. Age \< 4 years for villages randomised to moxidectin, diethylcarbamazine, and albendazole (MoxDA); or 6. Age \< 2 years or weight \< 15 kg for villages randomized to ivermectin, diethylcarbamazine and albendazole (IDA).

Conditions

Lymphatic Filariasis Scabies Strongyloidiasis

Locations

Ministry of Health and Medical Services Fiji — Suva, Fiji

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment